FDA expands use for ArthoCare's RF (radiofrequency) tools:
This article was originally published in Clinica
ArthroCare has received US FDA marketing clearance to expand the use of its radiofrequency (RF) arthroscopic surgical devices. The Sunnyvale, California firm has gained the go-ahead to use its Coblation-based disposable surgical devices in over 40 specific arthroscopic indications in the knee, shoulder, wrist, ankle, elbow and hip. The expanded clearance covers around 160 orthopaedic procedures and represents the broadest array of specific indications approved for any company marketing RF surgical equipment for arthroscopic and orthopaedic applications, the company claims. The devices were previously cleared for soft tissue resection, ablation, coagulation and haemostasis in general arthroscopic and orthopaedic procedures.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.